COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features

References

• AdlerCHSingerCO’BrienCRandomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group IIIArch Neurol1998551089959708959
   PubMedGoogle Scholar
• AntoniniAIsaiasIUCanesiMDuodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcomeMov Disord2007221145917661426
   PubMed Web of Science ®Google Scholar
• BaasHBeiskeAGGhikaJCatechol-O-methyltransferase inhibition with tolcapone reduces the “wearing off” phenomenon and levodopa requirements in fluctuating parkinsonian patientsJ Neurol Neurosurg Psychiatry19976342189343116
   PubMed Web of Science ®Google Scholar
• BlackKJHersheyTHartleinJMLevodopa challenge neuroimaging of levodopa-related mood fluctuation in Parkinson’s diseaseNeuropsychopharmacology20053059060115602502
   PubMed Web of Science ®Google Scholar
• BonuccelliUDel DottoPLucettiCDiurnal motor variations to repeated doses of levodopa in Parkinson’s diseaseClin Neuropharmacol200023283310682228
   PubMed Web of Science ®Google Scholar
• BorgesNTolcapone in Parkinson’s disease: liver toxicity and clinical efficacyExpert Opin Drug Saf20054697315709899
   PubMedGoogle Scholar
• CaraceniTMusiccoMLevodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson’s disease. A randomized multicenter studyParkinsonism Relat Disord200171071411248591
   PubMed Web of Science ®Google Scholar
• CeravoloRPicciniPBaileyDL18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson’s disease. These findings are compatible with clinical doses of tolcapone having a significant blocking effect on peripheral and central COMT but not DDC activity in PDSynapse200243201711793426
   PubMed Web of Science ®Google Scholar
• ChaudhuriKRMartinez-MartinPBrownRGThe metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot studyMov Disord20072219011117674410
   PubMed Web of Science ®Google Scholar
• ChaudhuriKRMartinez-MartinPSchapiraAHInternational multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMS Quest studyMov Disord2006219162316547944
   PubMed Web of Science ®Google Scholar
• ColosimoCThe rise and fall of tolcaponeJ Neurol1999246880210552233
   PubMed Web of Science ®Google Scholar
• DeaneKHSpiekerSClarkeCECatechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson’s diseaseCochrane Database Syst Rev2004182005
   Google Scholar
• DefebvreLMotor complications in DOPA treatment of Parkinson’s disease: clinical description and evaluationTherapie20045993615199675
   PubMed Web of Science ®Google Scholar
• European Medicines Evaluation AgencyEMEA public statement on the lifting of the suspension of the marketing authorisation for Tolcapone (Tasmar) (online) Accessed 2004. URL: http://www.emea.eu.int
   Google Scholar
• FactorSAMolhoESFeustelPJLong-term comparative experience with tolcapone and entacapone in advanced Parkinson’s diseaseClinic Neuropharmacol2001242959
   PubMed Web of Science ®Google Scholar
• GoetzCGPoeweWRascolOEvidence based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004Mov Disord2005205233915818599
   PubMed Web of Science ®Google Scholar
• HalkiasIAHaqIHuangZWhen should levodopa therapy be initiated in Patients with Parkinson’s disease?Drugs Aging2007246173
   Web of Science ®Google Scholar
• HauserRAMcDermottMPMessingSFactors associated with the development of motor fluctuations and dyskinesias in Parkinson DiseaseArch Neurol20066317566017172616
   PubMed Web of Science ®Google Scholar
• KaakkolaSClinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s DiseaseDrugs20005912335010882160
   PubMed Web of Science ®Google Scholar
• LangAELozanoAMParkinson’s disease. Second of two parts (Review)N Engl J Med19983391130439770561
   PubMed Web of Science ®Google Scholar
• LauterbachECThe neuropsychiatry of Parkinson’s diseaseMinn Med20059615573
   Google Scholar
• Leegwater-KimJWatersCTolcapone in the management of Parkinson’s diseaseExpert Opin Pharmacother2006722637017059382
   PubMed Web of Science ®Google Scholar
• LeesAJAlternatives to levodopa in the initial treatment of early Parkinson’s diseaseDrugs Aging2005227314016156677
   PubMed Web of Science ®Google Scholar
• LeesAJRatziuVTolosaESafety and tolerability of adjunctive tolcapone therapy in early Parkinson’s disease patientsJ Neurol Neurosurg Psychiatry200778944817098835
   PubMed Web of Science ®Google Scholar
• LimousinPPollakPPfefenJPAcute administration of levodopa-beserazide and Tolcapone, a COMT inhibitor, in Parkinson’s diseaseClin Neuropharmacol199518258658635184
   PubMed Web of Science ®Google Scholar
• MaricleRANuttJGCarterJHMood and anxiety fluctuation in Parkinson’s disease associated with levodopa infusion: preliminary findingsMov Disord199510329327651451
   PubMed Web of Science ®Google Scholar
• MaricleRAValentineRJCarterJMood response to levodopa infusion in early Parkinson’s DiseaseNeurology199850189029633754
   PubMed Web of Science ®Google Scholar
• Martinez-MartinPChaudhuriKRStocchiFPrevalence of non-motor symptoms in Parkinson’s disease in an international setting; Study using non-motor symptoms questionnaire in 545 patientsMov Disord2007221623917546669
   PubMed Web of Science ®Google Scholar
• MurielMPOrieuxGHirschECLevodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian ratsMov Disord20021711747912465054
   PubMed Web of Science ®Google Scholar
• NapolitanoADel DottoPPetrozziLPharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson’s diseaseClin Neuropharmacol19992224910047930
   PubMed Web of Science ®Google Scholar
• NuttJGPharmacodynamics of levodopa in Parkinson’s diseaseClin Exp Pharmacol Physiol199522837408593740
   PubMed Web of Science ®Google Scholar
• NuttJGCarterJHWoodwardWREffect of brief levodopa holidays on the short-duration response to levodopa: evidence for tolerance to the antiparkinsonian effectsNeurology1994441617227936285
   PubMed Web of Science ®Google Scholar
• NuttJGHolfordNHGThe response to levodopa in Parkinsons’ disease: imposing pharmacological law and orderAnnals Neurol19963956173
   PubMed Web of Science ®Google Scholar
• OlanowCWTolcapone and hepatotoxic effects. Tasmar Advisory PanelArch Neurol200057263710681087
   PubMed Web of Science ®Google Scholar
• OlanowCWWattsRLKollerWCAn algorithm (decision tree) for the management of PD; 2001: treatment guidelinesNeurology200156Suppl 5S18811402154
   PubMed Web of Science ®Google Scholar
• OldfieldVKeatingGMPerryCMRasagiline: a second generation monoamine oxidase type B inhibitor for the treatment of Parkinson’s diseaseDrugs20076717254717683172
   PubMed Web of Science ®Google Scholar
• OnofrjMThomasAIaconoDSwitch-Over from tolcapone to entacapone in severe Parkinson’s disease patientsEur Neurol200146111611455177
   PubMed Web of Science ®Google Scholar
• Opacka-JuffryJBrooksDJL-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory rolesMov Disord19951024197651438
   PubMed Web of Science ®Google Scholar
• PahwaRFactorSALyonsKEPractice parameter: treatment of Parkinson Disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the quality Standards Subcommittee of the American Academy of NeurologyNeurology2006669839516606909
   PubMed Web of Science ®Google Scholar
• [PSG] Parkinson Study GroupImpact of deprenyl and tocopherol treatment on Parkinson’s Disease in DATATOP patients requiring levodopaAnn Neurol19963937458572664
   PubMed Web of Science ®Google Scholar
• [PSG] Parkinson Study GroupA controlled trial of rasagiline in early Parkinson disease: the TEMPO StudyArch Neurol20025919374312470183
   PubMedGoogle Scholar
• [PSG] Parkinson Study GroupA randomized placebo-controlled trial of rasagiline in levodopa – treated patients with Parkinson disease and motor fluctuations: the PRESTO studyArch Neurol200562241815710852
   PubMedGoogle Scholar
• QuattroneAZappiaMAgugliaUThe subacute levodopa test for evaluating long-duration response in Parkinson’s diseaseAnn Neurol199538389957668824
   PubMed Web of Science ®Google Scholar
• RajputAHMartinWSaint-HilaireMHTolcapone improves motor function in parkinsonian patients with the “wearing-off” phenomenon: a double-blind, placebo-controlled, multicenter trialNeurology1997491066719339691
   PubMed Web of Science ®Google Scholar
• RascolOGoetzCKollerWTreatment interventions for Parkinson’s disease: an evidence based assessmentLancet200235915899812047983
   PubMed Web of Science ®Google Scholar
• RascolOMelamedEOertelWRasagiline, as an adjunct to levodopa in patients with Parkinson’s disease and motor flucuations (LARGO, lasting effect in adjunct therapy with Rasagiline given once daily; study): a randomized, double-blind, parallel-group trialLancet20053659475415766996
   PubMed Web of Science ®Google Scholar
• RileyDELangAEThe spectrum of levodopa-related fluctuations in Parkinson’s diseaseNeurology1993431459648350996
   PubMed Web of Science ®Google Scholar
• SchragAQuinnNDyskinesias and motor fluctuations in Parkinson’s disease A community-based studyBrain2000123229730511050029
   PubMed Web of Science ®Google Scholar
• ShanDELeeSJChaoLYGait analysis in advanced Parkinson’s disease – effect of levodopa and tolcaponeCan J Neurol Sci20012870511252300
   PubMed Web of Science ®Google Scholar
• ShoulsonIOakesDFahnSImpact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trialAnn Neurol2002516041212112107
   PubMed Web of Science ®Google Scholar
• SuchowerskyOBaileyPPourcherEComparison of two dosages of Tolcapone added to levodopa in nonfluctuating patients with PDClin Neuropharmacol2001242142011479392
   PubMed Web of Science ®Google Scholar
• The Entacapone to Tolcapone Switch Study InvestigatorsEntacapone to tolcapone switch: multicenter double blind, randomized, active controlled trial in Advanced Parkinson’s diseaseMov Disord200722141917089403
   PubMed Web of Science ®Google Scholar
• Van LaarTLevodopa-induced response fluctuations in patients with Parkinson’s disease: strategies for managementCNS Drugs2003174758912751918
   PubMed Web of Science ®Google Scholar
• WatkinsPCOMT inhibitors and liver toxicityNeurology20005511 SupplS51211147510
   PubMed Web of Science ®Google Scholar
• WidnellKLComellaCRole of COMT Inhibitors and dopamine agonists in the treatment of motor fluctuationsMov Disord200520Suppl 11307
   Web of Science ®Google Scholar
• WitjasTKaphanEAzulayJPNonmotor fluctuations in Parkinson’s disease: frequent and disablingNeurology2000594081312177375
   PubMed Web of Science ®Google Scholar
• ZappiaMAnnesiGNicolettiGSex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory studyArch Neurol200562601515824260
   PubMed Web of Science ®Google Scholar
• ZappiaMBoscoDPlastinoMPharmacodynamics of the long-duration response to levodopa in PDNeurology1999a535576010449120
   PubMed Web of Science ®Google Scholar
• ZappiaMColaoRMontesantiRLong-duration to levodopa influences the pharmacodynamics of short-duration response in Parkinson’s diseaseAnn Neurol19974224589266736
   PubMed Web of Science ®Google Scholar
• ZappiaMOlivieriRLBoscoDThe long-duration response to L-dopa in the treatment of early PDNeurology2000542475010636162
   PubMed Web of Science ®Google Scholar
• ZappiaMOlivieriRLMontesantiRLoss of long-duration response to levodopa over time i0Implications for wearing-offNeurology1999b52763710078724
   PubMed Web of Science ®Google Scholar